Knockdown of IGF2 mRNA-binding protein 2 (IGF2BP2) is noted to decrease the expression of long noncoding RNAs (lncRNAs) and tight junction–related proteins, thereby promoting BTB permeability in glioma and enhancing antitumor efficacy of certain drugs (Liu et al., 2020). Here, IGF2BP2 is linked to central nervous system cancer.